Aegerion Announces Second Quarter 2016 Financial Results
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business update for the second quarter of 2016.
Highlights
* Aegerion recorded total net product sales of $44.5 million in the second quarter of 2016.
* Aegerion recorded $31.1 million in net product sales of JUXTAPID® (lomitapide) capsules in the second quarter of 2016, $20.4 million, or 66% of which was from prescriptions written in the United States (U.S.). As of June 30, 2016, there were 423 active HoFH patients on JUXTAPID therapy globally, approximately 296 of whom are U.S. patients.
Highlights
* Aegerion recorded total net product sales of $44.5 million in the second quarter of 2016.
* Aegerion recorded $31.1 million in net product sales of JUXTAPID® (lomitapide) capsules in the second quarter of 2016, $20.4 million, or 66% of which was from prescriptions written in the United States (U.S.). As of June 30, 2016, there were 423 active HoFH patients on JUXTAPID therapy globally, approximately 296 of whom are U.S. patients.